[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"resistance\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:resistance":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,43,66],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100631638","genotype-and-subtype-mapping-of-the-hepatitis-c-virus-100631638",false,"NCT07503288","Genotype and Subtype Mapping of the Hepatitis C Virus","Cartographie Des génotypes et Sous-types du Virus de l'hépatite C","CARTO-VHC","Inclusion Criteria:\n\n* Patient aged 18 years old or more\n* Newly diagnosed patient positive for HCV (presence of HCV antibodies)\n* Patient with active infection (HCV RNA \\> 0)\n\nExclusion Criteria:\n\n* Patients who decline to participate in the study and oppose the use of their personal data\n* Patients under legal protection (guardianship or curatorship)","ALL","18 Years",{"count":20,"type":21},2500,"ESTIMATED","OBSERVATIONAL","Chronic hepatitis C virus (HCV) infection is the second leading cause of primary liver cancer worldwide and the leading cause in the United States. In 2020, an estimate 260,000 deaths were attributable to HCV globally, nearly 80,000 of which occurred in Europe, mainly due to complications such as cirrhosis or hepatocellular carcinoma (HCC).\n\nThe CARTO-VHC study is a retrospective, observational, multicenter study based on data and samples collected during routine care from 2023 to 2024. The study does not involve direct human participation. The study aims to describe the different genotypes and subtypes of the hepatitis C virus, including unusual subtypes, in a large population of newly diagnosed HCV-positive patients. This will help identify the most common types circulating in France. Additionally, the study will provide a comprehensive understanding of therapeutic failures and drug resistance to direct-acting antivirals (DAA) in treated patients.",[25,26,27,28,29],"Hepatitis C Virus","Mutation Abnormality","RNA Positive","Unusual Subtype","Resistance","NOT_YET_RECRUITING","2026-05-15",{"date":33,"type":34},"2026-05-19","ACTUAL",{"date":36,"type":21},"2026-06-01",{"date":38,"type":21},"2029-03",{"name":40,"class":41},"Assistance Publique - Hôpitaux de Paris","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":18,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":4},"100611528","predictors-of-drug-resistant-epilepsy-among-pediatric-patients-100611528","NCT07241754","Predictors of Drug Resistant Epilepsy Among Pediatric Patients","Predictors of Anti-seizure Medication Resistance in Pediatric Epilepsy","Inclusion Criteria:\n\n* Children aged 1-18 years with a confirmed diagnosis of epilepsy.\n* Both males and females will be included.\n\nExclusion Criteria:\n\n* Children younger than 1 year or older than 18 years.\n* Patients with acute symptomatic seizures (e.g., febrile seizures, metabolic or infectious causes) or pseudo refractory epilepsy (e .g. syncope or uncorrect ASMs)\n* Patients controlled on antiseizure medications\n* Refusal of parents or guardians to participate in the study","1 Year",{"count":52,"type":21},200,"1. This study aims to determine the main predictors of drug resistance in pediatric epilepsy by examining clinical data, EEG abnormalities, and neuroimaging results, in order to support early identification of resistant cases and improve treatment strategies .\n2. Early introduction of new lines of treatment in case of refractory epilepsy as : Ketogenic diet , Rituximab and solumedrol",[55,56,29],"Epilepsy","Seizure","2025-12-09",{"date":59,"type":34},"2025-12-17",{"date":61,"type":21},"2025-12-29",{"date":63,"type":21},"2027-02-01",{"name":65,"class":41},"Assiut University",{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":72,"enrollmentInfo":73,"targetDuration":75,"studyType":22,"phases":4,"briefSummary":76,"conditions":77,"keywords":81,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":4},"100569429","real-world-observational-study-of-targeted-therapy-in-patients-with-advanced-ros1-positive-nsclc-100569429","NCT06694129","Real-world Observational Study of Targeted Therapy in Patients With Advanced ROS1-positive NSCLC","Inclusion Criteria:\n\n* 1\\) Histologically or cytologically confirmed non-small cell lung cancer;\n* 2\\) TNM stage of the ninth edition is IIIB, IIIC, or IV;\n* 3\\) ROS1 fusion positive confirmed by one of the following qualified results: next-generation sequencing technology, fluorescence in situ hybridization, reverse transcription polymerase chain reaction;\n* 4\\) No prior systemic chemotherapy, radiation therapy, or surgery;\n* 5\\) Aged 18 years or older;\n* 6\\) ECOG PS score of 0-1.\n\nExclusion Criteria:\n\n* 1\\) any prior history of NSCLC and\u002For any prior treatment for NSCLC;\n* 2\\) prior systemic chemotherapy or radiation therapy or surgical treatment;\n* 3\\) the presence of a second primary tumor;\n* 4\\) hypersensitivity to ROS1-TKI or intolerance to it.","86 Years",{"count":74,"type":21},40,"3 Years","The purpose of this project is to conduct an observational study on the efficacy and safety of entrectinib in real-world patients with ROS1-positive NSCLC who have received entrectinib treatment, while exploring the mechanism of entrectinib's brain protection and resistance mechanism. Because this study is a non-interventional study, it will not interfere with your usual treatment. However, your medical data will be analyzed, and the results will help improve future treatment options for ROS1 positive NSCLC patients and improve their quality of life.This study was divided into three cohorts. Cohort 1: For patients with advanced ROS1-positive NSCLC who met the inclusion criteria and had not received TKI treatment, they were treated with entrectinib until disease progression or intolerance (N=15); Cohort 2: For patients with advanced ROS1-positive NSCLC who met the inclusion criteria and had received first-generation ROS1 TKI treatment with disease progression on crizotinib, they were treated with entrectinib until disease progression or intolerance (N=15); Cohort 3: For patients with ROS1-positive NSCLC who had failed multiple lines of treatment, they were treated with entrectinib until disease progression or intolerance (N=10). Regular follow-up was conducted and relevant clinical data were recorded, followed by Cox regression analysis and survival analysis. The information that needs to be recorded includes baseline and treatment genetic testing, demographic information, anti-cancer history, and concomitant medication use, as well as the use of study drugs and adverse events during treatment visits, survival and subsequent drug use after discharge, and the follow-up frequency consistent with clinical practice. Subjects are eligible for a complimentary NGS test upon the development of entrectinib resistance.",[78,79,29,80],"Non-Small Cell Lung Cancer","ROS1 Gene Rearrangement","Targeted Therapy",[78,79,82],"Targeted therapy","2024-11-16",{"date":85,"type":34},"2024-11-19",{"date":87,"type":21},"2024-12-01",{"date":89,"type":21},"2027-12-01",{"name":91,"class":41},"National Cancer Center, China"]